Investigational New Drug (IND)
Investigational New Drug (IND) enabling studies are a matrix of tests that must be conducted before a new therapeutic can be administered to the intended population. Depending on the results of each nonclinical study, the test article could take several different paths to complete the series of studies. In contrast to the common characterization of a drug development “pipeline” being a unidirectional flow from discovery to utilization, a diverse map of potentially failure-prone learning maps must be navigated by scientists with multiple backgrounds. It is vital to find a CRO with the experience and expertise to help steer the drug through the complex maze of tests. This is where Attentive Science comes in. Attentive will work with you to successfully complete your IND-enabling program. With our significant experience and knowledge of multiple therapeutics and new chemical entities we have come to know what to expect ahead of time. Attentive is a boutique CRO, which allows us to pivot quickly in response to unexpected results. Our Client Calibrated Approach allows us to quickly communicate unexpected challenges to clients, discuss creative solutions and deliver trustworthy data quickly.